nct_id: NCT06619587
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-10-01'
study_start_date: '2024-11-14'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Phase I Arm A'
  - drug_name: 'Drug: Phase I Arm B'
long_title: A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety,
  Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination
  With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS
  G12D Mutation
last_updated: '2025-11-17'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Genentech, Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 410
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Histologically documented advanced or metastatic solid tumor with KRAS G12D mutation'
- '* Agreement to adhere to the contraception requirements described in the protocol
  for participants of childbearing potential and participants who produce sperm'
- 'Exclusion criteria:'
- '* Malabsorption or other condition that would interfere with enteral absorption'
- '* Active brain metastases'
- '* Clinically significant cardiovascular dysfunction or liver disease'
short_title: A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035
  as a Single Agent and in Combination in Patients With Advanced Solid Tumors
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Genentech, Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation
  and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary
  activity of GDC-7035 as a single agent and in combination with other anti-cancer
  therapies in participants with advanced or metastatic solid tumors that harbor the
  KRAS G12D mutation.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Phase I Arm A
      arm_internal_id: 0
      arm_description: Dose escalation and expansion arm
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Phase I Arm A'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Phase I Arm B
      arm_internal_id: 1
      arm_description: Dose escalation and expansion arm
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Phase I Arm B'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Advanced
          - Metastatic
          oncotree_primary_diagnosis: _SOLID_
      - or:
        - genomic:
            hugo_symbol: KRAS
            variant_category: Mutation
